Skip to main content
  • English
  • Español
Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
      • Share Performance
      • Shares and Capital Structure
      • Dividends
      • Share Issues
      • Takeover Bids
      • Shareholdings
    • Financial Information
      • Financial Results and Accounts
      • Public Periodic Information
      • Average supplier payment period
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
      • General Shareholders Meeting
      • Board of Directors
      • Board Committees
      • Shareholder Agreements
      • Annual Corporate Governance Reports
      • Annual Director Remuneration Reports
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us

Breadcrumb

  1. Home
1 June 2018

Oryzon to present at upcoming international conferences

30 May 2018

Oryzon Genomics reaffirms its commitment to the research in neurodegenerative diseases on the World Multiple Sclerosis Day

29 May 2018

ORYZON receives approval in the United Kingdom to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

14 May 2018

ORYZON announces First Patients In ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

9 May 2018

ORYZON Reports Financial Results and Corporate Update for the 1st Quarter 2018

8 May 2018

ORYZON receives approval in France to start ETHERAL: a Phase IIa clinical trial in Alzheimer’s Disease with ORY-2001

3 May 2018

ORYZON covered for the first time by a US investment bank: ROTH Capital Partners

29-31 May 2018

Foro MEDCAP2018

Madrid Stock Exchange Palace

Spain

24 May 2018

15th Anglonordic Life Science conference

County Hall, Riverside Building, Belvedere Road

London SE1 7PB

United Kingdom

14-16 May 2018

Bio€quity Europe 2018

Het Pand

Ghent

Belgium

Pagination

  • First page « First
  • Previous page ‹ Previous
  • Page 38
  • Page 39
  • Page 40
  • Page 41
  • Current page 42
  • Page 43
  • Page 44
  • Page 45
  • Page 46
  • Next page Next ›
  • Last page Last »
Subscribe to
Logo Oryzon
  • Company
    • Overview
    • Strategy
    • Team
  • Epigenetics
    • Epigenetics
    • LSD1
  • Programs
    • Pipeline
    • Iadademstat
    • Vafidemstat
    • Collaborations
    • Publications
  • Patients
    • Clinical Trials
  • Investors
    • Share Information
    • Financial Information
    • CNMV Filings
    • Analyst Coverage
    • Corporate Governance
    • Corporate Social Responsibility
  • News & Events
    • Press releases
    • Events
  • Contact
    • Contact
    • Email Alerts
    • Join us
  • © Oryzon Genomics, S.A. - All Rights Reserved

    • Legal
    • Privacy Policy
    • Cookie Policy
    • Ethics Channel